Allergy Therapeutics To Enter U.S. Allergy Market With 2019 Launch
This article was originally published in The Pink Sheet Daily
Launch of the first FDA-approved subcutaneous allergy vaccine may be four years away, but the European specialty company is starting to plan for commercialization and market growth.
You may also be interested in...
Mereo BioPharma’s completed private placement in the US will support clinical studies of its candidate immuno-oncology product etigilimab and a later-stage anti-sclerotin antibody product with potential in the treatment of brittle bone disease.
Novartis will not start to compete in the increasingly crowded US multiple sclerosis marketplace with ofatumumab this month, as regulators extend the review process for the B-cell depleting therapy until September.
Verona Pharma’s candidate COPD therapy ensifentrine has a first-in-class dual mechanism of action and is to be explored as an add-on to LAMA and LABA therapy in two Phase III clinical studies.